DE60217336D1 - Verwendung eines pyridazinon derivates zur behandlung des kongestiven herzversagens - Google Patents

Verwendung eines pyridazinon derivates zur behandlung des kongestiven herzversagens

Info

Publication number
DE60217336D1
DE60217336D1 DE60217336T DE60217336T DE60217336D1 DE 60217336 D1 DE60217336 D1 DE 60217336D1 DE 60217336 T DE60217336 T DE 60217336T DE 60217336 T DE60217336 T DE 60217336T DE 60217336 D1 DE60217336 D1 DE 60217336D1
Authority
DE
Germany
Prior art keywords
heart failure
congestive heart
treatment
pyridazinone derivatives
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60217336T
Other languages
English (en)
Other versions
DE60217336T2 (de
Inventor
Heimo Haikala
Esa-Pekka Sandell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Original Assignee
Orion Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Oyj filed Critical Orion Oyj
Publication of DE60217336D1 publication Critical patent/DE60217336D1/de
Application granted granted Critical
Publication of DE60217336T2 publication Critical patent/DE60217336T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60217336T 2001-07-04 2002-07-04 Verwendung eines pyridazinon derivates zur behandlung des kongestiven herzversagens Expired - Lifetime DE60217336T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20011465 2001-07-04
FI20011465A FI20011465A0 (fi) 2001-07-04 2001-07-04 Pyridatsinonijohdannaisen uusi käyttö
PCT/FI2002/000605 WO2003004035A1 (en) 2001-07-04 2002-07-04 New use of a pyridazinone derivative

Publications (2)

Publication Number Publication Date
DE60217336D1 true DE60217336D1 (de) 2007-02-15
DE60217336T2 DE60217336T2 (de) 2007-10-04

Family

ID=8561590

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60217336T Expired - Lifetime DE60217336T2 (de) 2001-07-04 2002-07-04 Verwendung eines pyridazinon derivates zur behandlung des kongestiven herzversagens

Country Status (9)

Country Link
US (1) US20040180895A1 (de)
EP (1) EP1401450B1 (de)
JP (1) JP2004535457A (de)
AT (1) ATE350101T1 (de)
CA (1) CA2450821A1 (de)
DE (1) DE60217336T2 (de)
ES (1) ES2278930T3 (de)
FI (1) FI20011465A0 (de)
WO (1) WO2003004035A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20040674A0 (fi) 2004-05-12 2004-05-12 Orion Corp Menetelmä tromboembolisten sairauksien estoon
MX2017004842A (es) * 2014-10-15 2017-06-22 Orion Corp Levosimendan para uso en el tratamiento de enfermedades de las neuronas motoras (por ejemplo esclerosis lateral amiotrofica).
EP3993773A1 (de) 2019-07-01 2022-05-11 Orion Corporation Verfahren zur verabreichung (r)-n-[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamid
US11969424B2 (en) 2019-12-16 2024-04-30 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4397854A (en) * 1981-05-14 1983-08-09 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
US4517310A (en) * 1981-07-28 1985-05-14 Berlex Laboratories, Inc. N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-1H-benzimidazole-1-butanamine and use thereof as a cardiotonic agent
US4432979A (en) * 1981-10-26 1984-02-21 William H. Rorer, Inc. Pyridone compounds
JP3131845B2 (ja) * 1991-06-12 2001-02-05 帝国臓器製薬株式会社 慢性心不全治療剤
FI973804A (fi) * 1997-09-26 1999-03-27 Orion Yhtymae Oy Levosimendaanin oraalisia koostumuksia
FI980901A (fi) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaania säädellysti vapauttavia oraalisia koostumuksia
US5905078A (en) * 1998-06-19 1999-05-18 Orion Corporation Use of a pyridazinone derivative
FI20011464A0 (fi) * 2001-07-04 2001-07-04 Orion Corp Yhdistelmäterapia sydämen vajaatoiminnan hoitoon

Also Published As

Publication number Publication date
US20040180895A1 (en) 2004-09-16
CA2450821A1 (en) 2003-01-16
WO2003004035A1 (en) 2003-01-16
DE60217336T2 (de) 2007-10-04
EP1401450B1 (de) 2007-01-03
ES2278930T3 (es) 2007-08-16
ATE350101T1 (de) 2007-01-15
JP2004535457A (ja) 2004-11-25
EP1401450A1 (de) 2004-03-31
FI20011465A0 (fi) 2001-07-04

Similar Documents

Publication Publication Date Title
EA200300906A1 (ru) Новые спиротрициклические производные и их применение в качестве ингибиторов фосфодиэстеразы-7
IS8058A (is) Sýklísk súlfónamíð til að hamla gamma seytiasa
MX2007004041A (es) Fenilpirazoles.
ATE373474T1 (de) Substituierte 2-aminotetraline zur behandlung von depressionen
NO20065079L (no) Materialer og metoder for behandling av koaguleringssykdommer
NO992282D0 (no) Benzonaftyridiner som bronkialterapentika
NO970164L (no) Anvendelse av tiazol- og tiadiazolforbindelser som D3 - dopaminreseptorligander
DE60127537D1 (de) VERWENDUNG VON 2-(4-ETHOXY-PHENYL)-3-(4-METHANESULFONYL-PHENYL)-PYRAZOLOÄ1,5-bÜPYRIDAZINE ZUR BEHANDLUNG VON NICHTULZERATIVER DYSPEPSIE
ATE429916T1 (de) Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
DE60217336D1 (de) Verwendung eines pyridazinon derivates zur behandlung des kongestiven herzversagens
DK0683777T3 (da) Oxindol-1-N-(alkoxycarbonyl)carboxamider og -1-(N-carboxamido)carboxamider som antiinflammatoriske midler
IL140032A0 (en) New use of a pyridazinone derivative
MA27812A1 (fr) Utilisation d'un inhibiteur de tyrosine kinase c-abl, pdgf-r ou c-kit dans le traitement du diabete
SE0103509D0 (sv) Rosuvastatin in pre demented states
EA200500242A1 (ru) Пиперидин-2,5-дионовые памоатные соли и их использование для лечения связанных со стрессом аффективных расстройств
DE60318089D1 (de) Protein-tyrosine-kinase-inhibitoren
BR0312242A (pt) 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil]-benzamida para o tratamento da fibrose pulmonar
ATE245986T1 (de) Verwendung von 8-nitro-2,3,4,5-tetrahydro-1h-3- benzazepinen zur herstellung von pharmazeutischen zusammenstellungen zur behandlung von schlafstörungen
DE60122171D1 (de) Verwendung von substituierten pyrazolen zur herstellung eines medikaments zur behandlung von allergien
ATE326970T1 (de) Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n 4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl benzamid zur behandlung von seminomen
DE60216441D1 (de) Mittel zur verbesserung der gewebepenetration

Legal Events

Date Code Title Description
8364 No opposition during term of opposition